H.C. Wainwright Reiterates Their Buy Rating on Marinus (MRNS)

By Austin Angelo

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Marinus (MRNSResearch Report), with a price target of $5.00. The company’s shares closed last Monday at $1.13, close to its 52-week low of $0.77.

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.9% and a 44.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Minerva Neurosciences, and Amag Pharmaceuticals.

Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $5.67, which is a 406.3% upside from current levels. In a report issued on November 7, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $5.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.00 and a one-year low of $0.77. Currently, Marinus has an average volume of 1.35M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.